Hims & Hers donates $1 million to Trump’s inauguration fund

Hims & Hers donates  million to Trump’s inauguration fund


Hims & Hers Health has donated $1 million to President-elect Donald Trump’s inauguration fund, CNBC confirmed Tuesday.

The company, which offers a range of direct-to-consumer treatments for conditions like weight loss, erectile dysfunction and hair loss, is the latest in a string of tech companies that have tried to curry favor with the incoming administration. OpenAI CEO Sam Altman and Meta both announced $1 million donations to the inaugural fund late last year, and Amazon and Apple CEO Tim Cook have also reportedly contributed.

“At Hims & Hers, we stand with leaders and advocates who are committed to improving America’s broken healthcare system,” the company said in a statement to CNBC.

Axios first reported Hims & Hers’ donation.

Hims & Hers was a breakout star in the digital health sector last year, largely thanks to the success of its popular new weight loss offering.

The company began prescribing compounded semaglutide through its platform in May after launching a weight loss program late in 2023. Semaglutide is the active ingredient in Novo Nordisk’s blockbuster medications Ozempic and Wegovy, which can cost around $1,000 a month without insurance. Compounded semaglutide is a cheaper, custom-made alternative to the brand drugs and can be produced when the brand-name treatments are in shortage.

The future of compounded GLP-1s in the U.S. is not entirely clear, especially as members of Trump’s circle have expressed conflicting opinions about the drugs more broadly. Robert F. Kennedy Jr.,  Trump’s pick to lead the Department of Health and Human Services, has criticized GLP-1s. He told CNBC in an interview that “the first line of response” to obesity should be lifestyle changes, though he added that “GLP drugs have a place.”

Dr. Marty Makary, Trump’s pick to lead the Food and Drug Administration, has served as an executive of the telehealth company Sesame, which connects consumers to physicians who can prescribe compounded GLP-1s. However, Makary’s role at Sesame has been mostly ceremonial in recent years. 

Elon Musk, the Tesla CEO who has been a close confidant of Trump’s since the election, has openly expressed his support for the medications.

“Nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public,” Musk wrote in a post on his social media platform X in December.

At an event with reporters in New York City late last year, which was attended by CNBC, Hims & Hers said it would work with the incoming administration and share the company’s point of view about the value of the medications.



Source

JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More
How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More